Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.

Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.

A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 110.sup.10 CFU/g, and a viability loss of less than 1 log unit/g after 3 months at a temperature of 40 C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.

A reduced coenzyme Q.sub.10-containing composition has high water solubility and excellent storage stability. A powder composition contains the reduced coenzyme Q.sub.10, starch octenylsuccinate, and gum Arabic. A method of producing the powder composition includes homogenizing the ingredients in water to obtain an emulsion composition; and drying the composition.

The present invention relates to a pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients. The present invention specifically relates to oral pharmaceutical composition of ferric citrate and one or more pharmaceutically acceptable excipients. Further, the present invention relates to stable pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt which improves patient compliance by enhancing ease of administration of the above mentioned pharmaceutical composition. Moreover, the present invention describes the methods employed for manufacturing the above mentioned oral pharmaceutical composition of ferric citrate.

The present invention relates to: a composition for transdermal delivery, comprising 1) a nanoemulsion comprising an active ingredient, saturated lecithin, phytosteryl/behenyl/octyldodecyl lauroyl glutamate, a polyol, and water, and 2) a modified layered double hydroxide; and a preparation method therefor.

The present invention relates to: a composition for transdermal delivery, comprising 1) a nanoemulsion comprising an active ingredient, saturated lecithin, phytosteryl/behenyl/octyldodecyl lauroyl glutamate, a polyol, and water, and 2) a modified layered double hydroxide; and a preparation method therefor.

Compositions including metabolites that are small molecules, and salts and derivatives thereof, and methods for treatment or prophylaxis of conditions related to the quality of aging are provided, including compositions and methods for treating conditions that negatively impact longevity and the quality of aging, including inflammation, anemia, hyperglycemia, dyslipidemia, hyperinsulinemia, liver disease, iron overload, impaired skin integrity, wound healing, scarring, pain, allergies, sleep disorders and problems, and gastrointestinal disorders and problems.

The present invention can provide: a prophylactic or ameliorating/therapeutic agent for chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, which contains a processed product of Japanese horseradish (wasabi) as an active ingredient; a food, a beverage, a medicine or a cosmetic, and a medicine for preventing or ameliorating/treating diseases relating to chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, each of which contains the processed product of wasabi; and methods for using these products.

The present invention can provide: a prophylactic or ameliorating/therapeutic agent for chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, which contains a processed product of Japanese horseradish (wasabi) as an active ingredient; a food, a beverage, a medicine or a cosmetic, and a medicine for preventing or ameliorating/treating diseases relating to chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, each of which contains the processed product of wasabi; and methods for using these products.